Biogen to buy Reata for $6.5 bln to bulk up rare disease portfolio
Biogen, a leading biotechnology company, has recently announced its plan to acquire Reata Pharmaceuticals for a staggering $6.5 billion. Biogen…
All information in one place
Biogen, a leading biotechnology company, has recently announced its plan to acquire Reata Pharmaceuticals for a staggering $6.5 billion. Biogen…